Stay tuned and follow the latest developments and news in Molecular Oncology.
The study by the Genekor Scientific Team, titled “RediScore: Prospective Validation of a Pipeline for Homologous Recombination Deficiency Analysis,” was published in Oncology Letters
The study by the Genekor Scientific Team, titled “RediScore: Prospective Validation of a Pipeline for Homologous Recombination Deficiency Analysis,” was published in Oncology Letters. This particular study investigates the analysis of tumor genomic instability as a biomarker of response to poly (ADP-ribose) polymerase inhibitors (PARPs) therapy. Inhibitors of poly (ADP-ribose) polymerases (PARPs) are established anticancer drugs and are used to target cancer cells with a dysfunctional homologous recombination (HR) repair pathway.
Therefore, PARP inhibitors (PARPi) are approved in ovarian, breast, prostate and pancreatic cancers, and clinical studies are ongoing in other cancer types.This study describes the validation of the RediScore test method and demonstrates its clinical utility in a group of 444 patients with ovarian cancer.
Read the entire publication:: https://pubmed.ncbi.nlm.nih.gov/37809048/